US justice department says pay-for-delay pharma deals may be unlawful
This article was originally published in SRA
Executive Summary
The US Department of Justice has told an appeals court that payments made by branded pharmaceutical companies to delay competition from generic drug manufacturers are “presumptively unlawful”. Companies involved in such “pay-for-delay” deals, it said, must justify their action to avoid antitrust liability1.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.